Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...

BOSTON -- Inhaled corticosteroids (ICS) combined either with formoterol (Foradil) or short-acting beta-agonists (SABA) for asthma treatment were associated with reduced risks of severe exacerbations ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under an ...

Please provide your email address to receive an email when new articles are posted on . The meta-analysis included 27 unique randomized controlled trials and 50,496 patients. Combinations improved ...

As reliever monotherapy for mild asthma, the inhaled corticosteroid (ICS)-formoterol combination reduced asthma attacks in children compared with a short-acting β₂-agonist (SABA), the CARE trial ...

A new study found that a 2-in-1 anti-inflammatory inhaler reduced asthma attacks in children by 45% compared to the widely-used salbutamol inhaler. The corresponding study was published in The Lancet.

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomised controlled trial to investigate the use of a ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

In the first randomised controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Inhalers have been key to asthma management since the 1950s. The most common, salbutamol, comes in a familiar blue-colored inhaler (or "puffer"). This kind of "rescue inhaler" brings quick relief from ...

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...